DE69218200T2 - Behandlung von leberkrebs - Google Patents

Behandlung von leberkrebs

Info

Publication number
DE69218200T2
DE69218200T2 DE69218200T DE69218200T DE69218200T2 DE 69218200 T2 DE69218200 T2 DE 69218200T2 DE 69218200 T DE69218200 T DE 69218200T DE 69218200 T DE69218200 T DE 69218200T DE 69218200 T2 DE69218200 T2 DE 69218200T2
Authority
DE
Germany
Prior art keywords
liver cancer
treatment
subject
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69218200T
Other languages
English (en)
Other versions
DE69218200D1 (de
Inventor
Arthur Bodgen
David Coy
Sun Kim
Jacques-Pierre Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Bioscience Inc
Original Assignee
Tulane University
Ipsen Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University, Ipsen Bioscience Inc filed Critical Tulane University
Publication of DE69218200D1 publication Critical patent/DE69218200D1/de
Application granted granted Critical
Publication of DE69218200T2 publication Critical patent/DE69218200T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69218200T 1991-05-10 1992-05-11 Behandlung von leberkrebs Expired - Fee Related DE69218200T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/698,681 US6083915A (en) 1991-05-10 1991-05-10 Method for treating liver cancer
PCT/US1992/003916 WO1992020363A1 (en) 1991-05-10 1992-05-11 Treatment of liver cancer

Publications (2)

Publication Number Publication Date
DE69218200D1 DE69218200D1 (de) 1997-04-17
DE69218200T2 true DE69218200T2 (de) 1997-09-25

Family

ID=24806255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69218200T Expired - Fee Related DE69218200T2 (de) 1991-05-10 1992-05-11 Behandlung von leberkrebs

Country Status (12)

Country Link
US (1) US6083915A (de)
EP (1) EP0588873B1 (de)
JP (2) JP3514754B2 (de)
AT (1) ATE149840T1 (de)
CA (1) CA2109206A1 (de)
DE (1) DE69218200T2 (de)
DK (1) DK0588873T3 (de)
ES (1) ES2101100T3 (de)
GR (1) GR3023645T3 (de)
HK (1) HK1006947A1 (de)
IE (1) IE921508A1 (de)
WO (1) WO1992020363A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100410274C (zh) * 2006-04-21 2008-08-13 暨南大学 特异性抗人肝癌噬菌体单链抗体HscFv 4－16基因及其应用
KR100814118B1 (ko) * 2006-10-17 2008-03-18 (주)국광플랜 문자나 도형 광고용 간판
KR100814120B1 (ko) * 2006-10-17 2008-03-18 (주)국광플랜 측광 및 후광을 이용한 문자나 도형 광고용 간판
EA200901142A1 (ru) * 2007-03-01 2010-04-30 Байер Шеринг Фарма Акциенгезельшафт 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
EP2719392B1 (de) 2008-06-12 2019-07-24 Ipsen Bioinnovation Limited Fusionproteine zur Verwendung bei der Behandlung von Akromegalie
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP2198878A1 (de) 2008-12-18 2010-06-23 University Of Miami Polypeptide Bombesinantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU618029B2 (en) * 1987-11-02 1991-12-12 Imperial Chemical Industries Plc Polypeptide compounds
GB8813356D0 (en) * 1988-06-06 1988-07-13 Ici Plc Polypeptide compounds
CA2042027A1 (en) * 1989-09-15 1991-03-16 Arthur E. Bogden Treatment of colon cancer

Also Published As

Publication number Publication date
EP0588873A4 (de) 1995-01-11
JP2004002331A (ja) 2004-01-08
EP0588873B1 (de) 1997-03-12
JP3514754B2 (ja) 2004-03-31
ATE149840T1 (de) 1997-03-15
CA2109206A1 (en) 1992-11-11
US6083915A (en) 2000-07-04
EP0588873A1 (de) 1994-03-30
DE69218200D1 (de) 1997-04-17
JPH06507633A (ja) 1994-09-01
HK1006947A1 (en) 1999-03-26
DK0588873T3 (da) 1997-09-15
GR3023645T3 (en) 1997-08-29
IE921508A1 (en) 1992-11-18
WO1992020363A1 (en) 1992-11-26
ES2101100T3 (es) 1997-07-01

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3888378T2 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
NO910340L (no) Topiske preparater for behandling av menneskenegler.
KR950700749A (ko) 2'-할로메틸리덴 유도체와 S-기 또는 M-기 특이성 항종양제를 사용하는 결합치료에 의한 암치료 방법(Method of treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M phase specific antineoplastic agent)
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DE3587741T2 (de) Behandlung von Hautkrankheiten.
DE68907423T2 (de) Behandlung der Akne.
DK71387D0 (da) Terapeutisk middel til behandling af psoriasis
DE3650620D1 (de) Behandlungsverfahren kataboler dysfunktion
DE69302439T2 (de) Topisches Präparat zur Verhütung oder Behandlung der Akne Vulgaris
DE3888994D1 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE69218200T2 (de) Behandlung von leberkrebs
SE9601395D0 (sv) New therapeutic treatment 1
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69325141D1 (de) Behandlung von lignozellulosehaltigen Materialien
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
DK0572549T3 (da) Behandling af ikke-småcellet lungecarcinom
DE69318949D1 (de) Behandlung von Eisenerzen
ATE72115T1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
BR9713828A (pt) Tratamento de tumores altamente vasculares

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOMEASURE, INC., HOPKINTON, MASS., US THE ADMINIS

8339 Ceased/non-payment of the annual fee